Pfizer has launched a new digital platform, PfizerForAll, aimed at simplifying the process of accessing healthcare for millions of Americans.
The platform provides an integrated experience for managing health and wellness, particularly for those affected by common illnesses and seeking adult vaccinations.
PfizerForAll consolidates critical resources and services, enabling individuals and families to take health actions such as obtaining care, filling prescriptions and finding potential savings on Pfizer medicines.
The platform operates within the US healthcare system and is developed in partnership with healthcare organisations.
Patients using PfizerForAll can leverage their existing insurance and pharmacy programmes while benefiting from new direct services from partners such as UpScriptHealth, Alto Pharmacy and Instacart.
At its inception, PfizerForAll offers same-day appointments with healthcare professionals for in-person or telehealth consultations, home delivery of prescription medicines, and scheduling for adult vaccinations against Covid-19, flu, RSV [respiratory syncytial virus] and pneumococcal pneumonia.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
The platform will also provide financial assistance and patient support services for Pfizer medicines, including co-pay cards and affordability programmes.
Pfizer chief US commercial officer and executive vice-president Aamir Malik stated: “People often experience information overload and encounter roadblocks when making decisions for themselves or their family in our complex and often overwhelming US healthcare system. This can be extremely time-consuming and lead to indecision or inaction – and as a result, poor health outcomes.
“We are pleased to offer PfizerForAll to help relieve this burden on people, especially as we enter the fall season in the US, and streamline the path for those seeking better health.”
In July 2024, the company posted a 98% decrease in net income attributable to common shareholders to $41m for the second quarter (Q2) of 2024, compared with $2.3bn in Q2 2023.
